Scholarlink

<p>Non-small cell lung cancer (NSCLC) is among the most common and lethal malignancies worldwide, representing a&#xa0;particular oncological challenge due to its frequent diagnosis at an advanced, metastatic stage. Histopathologically, NSCLC is broadly classified into adenocarcinomas and squamous cell carcinomas. This distinction—along with programmed cell death-ligand&#xa0;1 (PD-L1) expression and molecular pathology—guides therapeutic decision-making. At advanced stages, treatment options include not only traditional platinum-based chemotherapy but also immunotherapy with checkpoint inhibitors. Over the past decade, the rapid identification of actionable driver mutations has firmly established targeted therapies with tyrosine kinase inhibitors as a&#xa0;cornerstone of treatment, significantly improving the historically poor overall survival.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapie des metastasierten nichtkleinzelligen Lungenkarzinoms

  • 期刊论文

  • 发表日期：

    2026年1月13日

查看全文
  • Malte Verheyen,
  • Lea Ruge,
  • Felix John,
  • Lucia Nogova

摘要

Non-small cell lung cancer (NSCLC) is among the most common and lethal malignancies worldwide, representing a particular oncological challenge due to its frequent diagnosis at an advanced, metastatic stage. Histopathologically, NSCLC is broadly classified into adenocarcinomas and squamous cell carcinomas. This distinction—along with programmed cell death-ligand 1 (PD-L1) expression and molecular pathology—guides therapeutic decision-making. At advanced stages, treatment options include not only traditional platinum-based chemotherapy but also immunotherapy with checkpoint inhibitors. Over the past decade, the rapid identification of actionable driver mutations has firmly established targeted therapies with tyrosine kinase inhibitors as a cornerstone of treatment, significantly improving the historically poor overall survival.